Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21858350 | 0.89 | MCL1 (0.80) | MCL1KCNH2KDM4EMEN1MAPK1 | |
| SCHEMBL3499014 | 0.88 | MCL1 (0.78) | MCL1KCNH2KDM4EMEN1MAPK1 | |
| SCHEMBL15619301 | 0.87 | MCL1 (0.77) | MCL1KCNH2KDM4EMEN1MAPK1 | |
| SCHEMBL11686876 | 0.87 | MCL1 (0.77) | MCL1KCNH2KDM4EMEN1MAPK1 | |
| SCHEMBL14648196 | 0.87 | MCL1 (0.77) | MCL1KCNH2KDM4EMEN1MAPK1 | |
| SCHEMBL1385653 | 0.87 | MCL1 (1.00) | MCL1KCNH2KDM4EMEN1MAPK1 | |
| SCHEMBL31384138 | 0.83 | MCL1 (0.71) | MCL1KCNH2KDM4EMEN1MAPK1 | |
| SCHEMBL1065472 | 0.83 | MCL1 (0.71) | MCL1KCNH2KDM4EMEN1KMT2A | |
| SCHEMBL23665874 | 0.83 | MCL1 (0.70) | MCL1KCNH2KDM4EMEN1MAPK1 | |
| SCHEMBL11099277 | 0.83 | MCL1 (0.70) | MCL1KCNH2KDM4EMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100413882-C | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2008-08-27 | — | — | CN | claimed |
| CN-1578786-A | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2005-02-09 | — | — | CN | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| CN-113416216-B | High-activity Pt complex and preparation method and application thereof | 江苏南创化学与生命健康研究院有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113416216-B | High-activity Pt complex and preparation method and application thereof | 江苏南创化学与生命健康研究院有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113416216-A | High-activity Pt complex and preparation method and application thereof | 江苏南创化学与生命健康研究院有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-113416216-A | High-activity Pt complex and preparation method and application thereof | 江苏南创化学与生命健康研究院有限公司 | 2021-09-21 | — | — | CN | disclosed |
| US-10844032-B2 | Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3176172-B1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2020-01-29 | — | — | EP | disclosed |
| US-20190135818-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2019-05-09 | — | — | US | disclosed |
| EP-3470415-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D]PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-04-17 | — | — | EP | disclosed |
| EP-1697304-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2006066879-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | DEVGEN N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2005054176-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| CN-1578786-A | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2005-02-09 | — | — | CN | disclosed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | disclosed |
| US-4009994-A | Process and product of optical brightening with quaternized benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1977-03-01 | — | — | US | disclosed |
| US-3940417-A | Quaternised benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | MCL1 980/4885KCNH2 3383/4885KDM4E 3961/4885 |
| US-20190135818-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | FGFR1, FGFR3, FGFR4 | MCL1 2780/4885KCNH2 1512/4885KDM4E 712/4885 |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | MCL1 3552/4885KCNH2 44/4885KDM4E 3285/4885 |
| US-10844032-B2 | Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors | MCL1, BCL2L1, BCLAF1 | MCL1 1/4885KCNH2 3644/4885KDM4E 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.